Explain this page
Arphra AIPlain-English read on Boston Scientific Corporation’s valuationInsider signal · 90d
Balanced
Bought
$0
Sold
$0
Txns
0
Over the trailing 90 days insiders are balanced — $0 bought against $0 sold across 0 open-market Form-4 transactions. Much insider selling is scheduled (10b5-1); read the asymmetry, not any single print.
Open-market Form 4
· insider_tradesInsider transactions · last 365d
Net −$47.7M0 buys
| Insider | Role | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Mahoney Michael F | director, officer: Chairman, President & CEO | Sell | −1,200 | $112.9K | Feb 02, 2026 |
| Mahoney Michael F | director, officer: Chairman, President & CEO | Sell | −159,701 | $14.9M | Feb 02, 2026 |
| Butcher Arthur C | officer: EVP& Grp Pres, MedSurg & APAC | Sell | −17,313 | $1.8M | Dec 01, 2025 |
| Zane Ellen M | director | Sell | −12,891 | $1.3M | Nov 06, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −16,928 | $1.7M | Nov 03, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −29,472 | $2.9M | Nov 03, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −3,600 | $362.7K | Nov 03, 2025 |
| Zane Ellen M | director | Sell | −2,901 | $296.6K | Oct 28, 2025 |
| Zane Ellen M | director | Sell | −9,990 | $1.0M | Oct 27, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −8,245 | $815.5K | Oct 01, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −41,755 | $4.1M | Oct 01, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −21,830 | $2.3M | Sep 02, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −28,170 | $3.0M | Sep 02, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | −50,000 | $5.2M | Aug 01, 2025 |
Transaction mix · 365d
100%
Sells18 · $47.7M
Buys0 · $0
Top sellers · 365d
Fitzgerald Joseph Michael · officer: EVP & Group Pres, Cardiology−$25.7M
Mahoney Michael F · director, officer: Chairman, President & CEO−$15.0M
Butcher Arthur C · officer: EVP& Grp Pres, MedSurg & APAC−$3.6M
Transactions
18
0 buys · 18 sells
Bought
$0
Open market
Sold
$47.67M
Open market
Net flow
−$47.67M
Buys − sells
Transactions
| Insider | Role | Action | Shares | Price | Value | Trade date | Filing |
|---|---|---|---|---|---|---|---|
| Mahoney Michael F | director, officer: Chairman, President & CEO | Sell | 1,200 | $94.06 | $112.87K | Feb 02, 2026 | Feb 03, 2026 |
| Mahoney Michael F | director, officer: Chairman, President & CEO | Sell | 159,701 | $93.49 | $14.93M | Feb 02, 2026 | Feb 03, 2026 |
| Butcher Arthur C | officer: EVP& Grp Pres, MedSurg & APAC | Sell | 17,313 | $101.55 | $1.76M | Dec 01, 2025 | Dec 02, 2025 |
| Zane Ellen M | director | Sell | 12,891 | $98.28 | $1.27M | Nov 06, 2025 | Nov 06, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 16,928 | $99.76 | $1.69M | Nov 03, 2025 | Nov 04, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 29,472 | $99.14 | $2.92M | Nov 03, 2025 | Nov 04, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 3,600 | $100.75 | $362.69K | Nov 03, 2025 | Nov 04, 2025 |
| Zane Ellen M | director | Sell | 2,901 | $102.24 | $296.6K | Oct 28, 2025 | Oct 28, 2025 |
| Zane Ellen M | director | Sell | 9,990 | $101.13 | $1.01M | Oct 27, 2025 | Oct 28, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 8,245 | $98.91 | $815.48K | Oct 01, 2025 | Oct 01, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 41,755 | $98.38 | $4.11M | Oct 01, 2025 | Oct 01, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 21,830 | $104.89 | $2.29M | Sep 02, 2025 | Sep 03, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 28,170 | $105.85 | $2.98M | Sep 02, 2025 | Sep 03, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 50,000 | $104.63 | $5.23M | Aug 01, 2025 | Aug 04, 2025 |
| Butcher Arthur C | officer: EVP& Grp Pres, MedSurg & APAC | Sell | 17,313 | $104.63 | $1.81M | Aug 01, 2025 | Aug 04, 2025 |
| FUJIMORI YOSHIAKI | director | Sell | 2,901 | $106.99 | $310.38K | Jul 29, 2025 | Jul 30, 2025 |
| LUDWIG EDWARD J | director | Sell | 4,000 | $106.03 | $424.12K | Jul 25, 2025 | Jul 28, 2025 |
| Fitzgerald Joseph Michael | officer: EVP & Group Pres, Cardiology | Sell | 50,000 | $106.97 | $5.35M | Jul 01, 2025 | Jul 02, 2025 |
By insider
- Fitzgerald Joseph Michael−$25.75Mofficer: EVP & Group Pres, Cardiology0B · 9S
- Mahoney Michael F−$15.04Mdirector, officer: Chairman, President & CEO0B · 2S
- Butcher Arthur C−$3.57Mofficer: EVP& Grp Pres, MedSurg & APAC0B · 2S
- Zane Ellen M−$2.57Mdirector0B · 3S
- LUDWIG EDWARD J−$424.12Kdirector0B · 1S
- FUJIMORI YOSHIAKI−$310.38Kdirector0B · 1S
Beneficial ownership filings
Schedule 13D / 13G — investors holding more than 5% of BSX-US.
DB · acquisition_ownership100
| Filed | Reporting person | Form | Type | Aggregate owned | % Class | Sole voting | Shared voting | Citizenship | |
|---|---|---|---|---|---|---|---|---|---|
| May 06, 2026 | FMR LLC | — | HC | — | +5.10% | 0 | 0 | DELAWARE | SEC → |
| Apr 29, 2026 | Vanguard Capital Management | — | IA | — | +7.47% | 0 | 0 | PENNSYLVANIA | SEC → |
| Mar 26, 2026 | The Vanguard Group | — | IA | — | 0.00% | 0 | 0 | PENNSYLVANIA | SEC → |
| Aug 06, 2025 | FMR LLC | — | HC | — | +7.50% | 0 | 0 | DELAWARE | SEC → |
| Apr 17, 2025 | BlackRock, Inc. | — | HC | — | +7.60% | 0 | 0 | DELAWARE | SEC → |
| Apr 07, 2025 | FMR LLC | — | HC | — | +9.60% | 0 | 0 | DELAWARE | SEC → |
| Feb 10, 2022 | Boston Scientific Corporation | — | CO | — | +8.00% | 543.97K | 0 | — | SEC → |
| Feb 09, 2022 | The Vanguard Group - 23-1945930 | — | IA | — | +7.83% | 0 | 2.24M | Pennsylvania | SEC → |
| Feb 09, 2022 | Abigail P. Johnson | — | IN | — | +7.02% | 0 | 0 | United States of America | SEC → |
| Feb 09, 2022 | FMR LLC | — | HC | — | +7.02% | 12.18M | 0 | Delaware | SEC → |
| Feb 08, 2022 | (1) BlackRock, Inc. | — | HC | — | +9.00% | 113.56M | 0 | Delaware | SEC → |
| Feb 04, 2022 | Wellington Investment Advisors Holdings LLP | — | HC | — | +5.22% | 0 | 68.68M | — | SEC → |
| Feb 04, 2022 | Wellington Management Group LLP | — | HC | — | +5.22% | 0 | 68.68M | — | SEC → |
| Feb 04, 2022 | Wellington Group Holdings LLP | — | HC | — | +5.22% | 0 | 68.68M | — | SEC → |
| Feb 03, 2022 | Boston Scientific Corporation | — | CO | — | +36.00% | 0 | 0 | Delaware | SEC → |
| Feb 02, 2022 | 04-2747644 | — | IA | — | +6.10% | 78.27M | 0 | Delaware | SEC → |
| Feb 16, 2021 | 95-1411037 | — | IA | — | +0.50% | 7.28M | 0 | Delaware | SEC → |
| Feb 12, 2021 | Boston Scientific Corporation | — | CO | — | +16.80% | 5.99M | 0 | Delaware | SEC → |
| Feb 10, 2021 | The Vanguard Group - 23-1945930 | — | IA | — | +7.74% | 0 | 2.3M | Pennsylvania | SEC → |
| Feb 08, 2021 | Abigail P. Johnson | — | IN | — | +4.57% | 0 | 0 | United States of America | SEC → |
| Feb 08, 2021 | FMR LLC | — | HC | — | +4.57% | 5.35M | 0 | Delaware | SEC → |
| Feb 05, 2021 | (1) BlackRock, Inc. | — | HC | — | +9.50% | 121.51M | 0 | Delaware | SEC → |
| Feb 04, 2021 | Wellington Management Group LLP | — | HC | — | +5.40% | 0 | 71.22M | Massachusetts | SEC → |
| Feb 04, 2021 | Wellington Investment Advisors Holdings LLP | — | HC | — | +5.40% | 0 | 71.22M | Massachusetts | SEC → |
| Feb 04, 2021 | Wellington Group Holdings LLP | — | HC | — | +5.40% | 0 | 71.22M | Massachusetts | SEC → |
| Feb 14, 2020 | Capital World Investors ** | — | IA | — | +7.70% | 107.36M | 0 | Delaware | SEC → |
| Feb 12, 2020 | The Vanguard Group - 23-1945930 | — | IA | — | +7.82% | 2.16M | 376.86K | Pennsylvania | SEC → |
| Feb 07, 2020 | Abigail P. Johnson | — | IN | — | +9.15% | 0 | 0 | United States of America | SEC → |
| Feb 07, 2020 | FMR LLC | — | HC | — | +9.15% | 13.29M | 0 | Delaware | SEC → |
| Feb 05, 2020 | (1) BlackRock, Inc. | — | HC | — | +7.30% | 89.11M | 0 | Delaware | SEC → |
Showing 30 of 100 filings. All disclosures →
Top 10 holders · 8 quarters
13F position evolutionNo 13F history in
institutional_holders for BSX-US.